Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01472887 · ClinicalTrials.gov registry record · Phase 2

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Sanofi.

Completed
Registry status
Phase 2
Development phase
61
Enrollment target
20
Study locations

NCT01472887 is a Phase 2 study of Diffuse Large B Cell Lymphoma that has completed, run by Sanofi. The registered enrollment target is 61 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01472887, a Phase 2 study of Diffuse Large B Cell Lymphoma, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target
20
Study locations

Study Summary

Primary Objective: Participants achieving an Objective Response Rate Secondary Objective: * Progression Free Survival * Overall Survival * Response Duration * Safety

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG SAR3419

Study Locations (20)

Other

  • Investigational Site Number 056002 - Ghent
  • Investigational Site Number 056001 - Leuven
  • Investigational Site Number 203002 - Brno
  • Investigational Site Number 203003 - Prague
  • Investigational Site Number 203001 - Prague
  • Investigational Site Number 376003 - Jerusalem
  • Investigational Site Number 376002 - Tel Litwinsky
  • Investigational Site Number 380002 - Bergamo
  • Investigational Site Number 380004 - Bologna
  • Investigational Site Number 380008 - Mestre
  • Investigational Site Number 380001 - Milan
  • Investigational Site Number 380007 - Modena
  • Investigational Site Number 380003 - Palermo
  • Investigational Site Number 380006 - Pavia
  • Investigational Site Number 616003 - Brzozów
  • Investigational Site Number 616002 - Kielce
  • Investigational Site Number 616001 - Warsaw

Colorado

  • Investigational Site Number 840001 - Denver

Georgia

  • Investigational Site Number 840003 - Augusta

Idaho

  • Investigational Site Number 840005 - Boise

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2012-01
Est. Completion 2016-09
Phase Phase 2

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01472887

The ClinicalTrials.gov registry entry for NCT01472887 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (72% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SAR3419 is the first listed.

NCT01472887 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT01472887 about?

NCT01472887 is a clinical study titled "SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients". Primary Objective: Participants achieving an Objective Response Rate Secondary Objective: * Progression Free Survival * Overall Survival * Response Duration * Safety

What is the current status of trial NCT01472887?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2012-01. Estimated completion is 2016-09.

What conditions does trial NCT01472887 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT01472887?

The interventions under investigation include: SAR3419 (DRUG).

Who is sponsoring clinical trial NCT01472887?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01472887 being conducted?

This trial has 20 study locations across Colorado, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.